40 replies to this topic

[Hebbeh]

This is one of the studies that people that are following NR have been waiting for. I think I will continue to take NR.

 

Why would you not just use the cheaper NAM rather than the expensive NR since the study (which was done by Chromadex BTW) showed cheap NAM cleared 30% more virus than the more expensive NR?

 

NAM reduced viral load 8.3 fold while NR reduce viral load 6.4 fold.

[joesixpack]

Why would you not just use the cheaper NAM rather than the expensive NR since the study (which was done by Chromadex BTW) showed cheap NAM cleared 30% more virus than the more expensive NR?

 

NAM reduced viral load 8.3 fold while NR reduce viral load 6.4 fold.

Because I use it without any problems.

 

Why test fate?

[MikeDC]

Why would you not just use the cheaper NAM rather than the expensive NR since the study (which was done by Chromadex BTW) showed cheap NAM cleared 30% more virus than the more expensive NR?

NAM reduced viral load 8.3 fold while NR reduce viral load 6.4 fold.

Because NR has other benefits and NAM has other issues such as inhibiting NAD+ consumption and Sirt1.

[MikeDC]

This study applies to all viruses including cold and flu.

[MikeDC]

Because NR has other benefits and NAM has other issues such as inhibiting NAD+ consumption and Sirt1. In addition this is a cell line study. The Trammel paper showed Oral NR generates more NAD+ and NAM than NAM itself because a larger portion of NAM is removed from the body. See fig5. .

Attached Files

•  561E49DB-B45C-447A-9F1F-647C614D788E.png   699.42KB   0 downloads

Edited by MikeDC, 09 July 2020 - 12:38 PM.

[MikeDC]

In addition to viral inhibition, higher NAD+ also
2. Reduce IL-6 release and prevent cytokine storm and sepsis.
3. Prevent blood clots and stroke.

https://pubmed.ncbi....h.gov/30292134/
https://pubmed.ncbi....h.gov/17928647/

https://pubmed.ncbi....h.gov/20606253/


https://www.cell.com...(19)30940-4.pdf
https://www.ncbi.nlm...les/PMC6369115/

[Phoebus]

 

 

Level of IL-6 predicts respiratory failure in hospitalized symptomatic COVID-19 patients

 

 View ORCID ProfileTobias Herold, Vindi Jurinovic, Chiara Arnreich, Johannes C Hellmuth, Michael von Bergwelt-Baildon, Matthias Klein, Tobias Weinberger

doi: https://doi.org/10.1....04.01.20047381

 

Now published in Journal of Allergy and Clinical Immunology doi: 10.1016/j.jaci.2020.05.008

 

Abstract

The pandemic Coronavirus-disease 19 (COVID-19) is characterized by a heterogeneous clinical course. While most patients experience only mild symptoms, a relevant proportion develop severe disease progression with increasing hypoxia up to acute respiratory distress syndrome. The substantial number of patients with severe disease have strained intensive care capacities to an unprecedented level. Owing to the highly variable course and lack of reliable predictors for deterioration, we aimed to identify variables that allow the prediction of patients with a high risk of respiratory failure and need of mechanical ventilation Patients with PCR proven symptomatic COVID-19 infection hospitalized at our institution from 29th February to 27th March 2020 (n=40) were analyzed for baseline clinical and laboratory findings. Patients requiring mechanical ventilation 13/40 (32.5%) did not differ in age, comorbidities, radiological findings, respiratory rate or qSofa score. However, elevated interleukin-6 (IL-6) was strongly associated with the need for mechanical ventilation (p=1.2.10-5). In addition, the maximal IL-6 level (cutoff 80 pg/ml) for each patient during disease predicted respiratory failure with high accuracy (p=1.7.10-8, AUC=0.98). The risk of respiratory failure for patients with IL-6 levels of ≥ 80 pg/ml was 22 times higher compared to patients with lower IL-6 levels. In the current situation with overwhelmed intensive care units and overcrowded emergency rooms, correct triage of patients in need of intensive care is crucial. Our study shows that IL-6 is an effective marker that might be able to predict upcoming respiratory failure with high accuracy and help physicians correctly allocate patients at an early stage.

 

Yes Mike I do believe that is a fair point about IL-6. If NAD+ therapy can really dramatically reduce that then that is certainly a positive effect in regards to covid 

Edited by Phoebus, 10 July 2020 - 06:01 PM.

[MikeDC]

Yes Mike I do believe that is a fair point about IL-6. If NAD+ therapy can really dramatically reduce that then that is certainly a positive effect in regards to covid

There are a few mice studies that show sufficient NAD+ is required to control inflammatory response. When NAD+ is low, you will likely have cytokines storm. Supplementing NAD+ for hospital patients will prevent a lot of sepsis.

[Phoebus]

There are a few mice studies that show sufficient NAD+ is required to control inflammatory response. When NAD+ is low, you will likely have cytokines storm. Supplementing NAD+ for hospital patients will prevent a lot of sepsis.

 

what studies are those? 

[MikeDC]

what studies are those?

https://www.frontier...2019.02358/full
https://pubmed.ncbi....h.gov/29803807/

[MikeDC]

This is a study of NR’s effects on inflammation in PBMC of heart failure patients.
IL-6 was reduced by 32 fold. Remember covid-19 and flu kills old people by
Cytokines storm. This is a good demonstration that NR can prevent cytokines storm.


https://www.jci.org/...les/view/138538

Attached Files

•  79243473-27BA-4A16-AB7E-818894832E76.png   371.92KB   0 downloads